Press Release
-
Join EG BioMed at BIO Asia–Taiwan 2025!
EG BioMed is excited to participate in BIO Asia–Taiwan 2025, one of Asia’s most influential biotech events, taking place from July 24 to 27 at the Taipei Nangang Exhibition Center, Hall 1 (4th Floor). BIO Asia–Taiwan Exhibition 2025 Booth Map – EG BioMed @ BIO Asia–Taiwan 2025 About EG BioMed EG BioMed is dedicated to…
-
EG BioMed at ASCO｜ZFP30 cfDNA Methylation Test Shows Strong Early Detection Performance in the Western Population
In 2025, EG BioMed presented its ZFP30-targeting cfDNA methylation blood test, the EG-Pancreatic Blood Test-E1, at the ASCO Annual Meeting. The test demonstrated promising early detection results for pancreatic cancer, particularly among the Western population. This study builds on findings we shared at the AACR Annual Meeting in April 20251, where ZFP30 and ZNF781 were…
-
EG BioMed Presents TMEM240 Blood Test at AACR to Enhance Colorectal Cancer Prognostic Monitoring
Enhancing Prognostic Precision: The Role of TMEM240 Methylation in Colorectal Cancer Limitations of Current Testing Methods Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths globally. Traditional blood-based markers like CEA and CA19-9 often lack the sensitivity and timeliness needed to detect early disease progression or treatment response. There is a clear unmet need…